Table:
JAK2V617F-mutated ET	CALR-mutated ET
Age, sex	Older	Younger, M>F
Blood counts	Hemoglobin	Higher	Lower
Platelet	Lower	Higher
White blood count	Higher	Lower
Serum erythropoietin level	Lower	Higher
Thrombotic risk	Higher	Lower
Polycythemic risk	Cumulative risk 29% at 15 years	No transformation to PV
MF transformation risk	Conflicting results
Overall survival (OS)	Long-term OS similar to that in CALR-mutated ET	Long-term OS similar to that in JAK2V617F-mutated ET
Treatment implications	ET patients with CALR mutations are at a lower risk of thrombotic complications compared to those with JAK2 mutations; however, recommendations regarding modifications of current treatment based on mutation status have not been developed yet

Translate the diagram into Markdown format.

| <COLSPAN=2>  | JAK2V617F-mutated ET | CALR-mutated ET | 
 | --- | --- | --- | --- | 
 | Age, sex |  | Older | Younger, M>F | 
 | <ROWSPAN=3> Blood counts | Hemoglobin | Higher | Lower | 
 | Platelet | Lower | Higher | 
 | White blood count | Higher | Lower | 
 | <COLSPAN=2> Serum erythropoietin level | Lower | Higher | 
 | <COLSPAN=2> Thrombotic risk | Higher | Lower | 
 | <COLSPAN=2> Polycythemic risk | Cumulative risk 29% at 15 years | No transformation to PV | 
 | <COLSPAN=2> MF transformation risk |  | Conflicting results | 
 | <COLSPAN=2> Overall survival (OS) | Long-term OS similar to that in CALR-mutated ET | Long-term OS similar to that in JAK2V617F-mutated ET | 
 | <COLSPAN=2> Treatment implications |  | ET patients with CALR mutations are at a lower risk of thrombotic complications compared to those with JAK2 mutations; however, recommendations regarding modifications of current treatment based on mutation status have not been developed yet |